43,977 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Purchased by Private Advisor Group LLC

Private Advisor Group LLC bought a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 43,977 shares of the company's stock, valued at approximately $264,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ADPT. Ashton Thomas Securities LLC purchased a new position in shares of Adaptive Biotechnologies during the third quarter worth $34,000. KBC Group NV purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter worth $50,000. Townsquare Capital LLC purchased a new position in shares of Adaptive Biotechnologies during the third quarter worth $56,000. GAMMA Investing LLC purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter worth $59,000. Finally, Centiva Capital LP purchased a new position in shares of Adaptive Biotechnologies during the third quarter worth $80,000. Hedge funds and other institutional investors own 99.17% of the company's stock.

Insiders Place Their Bets

In related news, CEO Chad M. Robins sold 211,160 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $8.50, for a total transaction of $1,794,860.00. Following the completion of the sale, the chief executive officer now owns 2,576,701 shares of the company's stock, valued at approximately $21,901,958.50. This represents a 7.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kyle Piskel sold 10,320 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total transaction of $72,033.60. Following the sale, the chief financial officer now directly owns 269,010 shares of the company's stock, valued at approximately $1,877,689.80. This represents a 3.69 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 692,903 shares of company stock worth $5,552,572. Corporate insiders own 6.20% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ADPT shares. Scotiabank raised their target price on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 13th. BTIG Research lifted their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. Piper Sandler reaffirmed an "overweight" rating and set a $11.00 target price (up from $7.00) on shares of Adaptive Biotechnologies in a report on Thursday, February 20th. Finally, The Goldman Sachs Group lifted their target price on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a "neutral" rating in a report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $9.10.

Adaptive Biotechnologies Stock Down 5.4 %

Shares of Adaptive Biotechnologies stock traded down $0.42 on Friday, reaching $7.35. The company's stock had a trading volume of 2,535,894 shares, compared to its average volume of 1,668,279. The company has a market capitalization of $1.09 billion, a P/E ratio of -6.74 and a beta of 1.53. Adaptive Biotechnologies Co. has a 52-week low of $2.28 and a 52-week high of $8.95. The stock has a 50-day moving average price of $7.55 and a 200-day moving average price of $6.03.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative return on equity of 64.65% and a negative net margin of 89.12%. During the same period in the previous year, the firm earned ($0.30) earnings per share. Sell-side analysts forecast that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.